Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
08 2020
Historique:
received: 20 02 2020
revised: 20 04 2020
accepted: 27 04 2020
pubmed: 21 6 2020
medline: 31 12 2020
entrez: 21 6 2020
Statut: ppublish

Résumé

Malignant dysphagia is the most common symptom in advanced oesogastric cancers patients. Relief of dysphagia allows quality of life improvement, nutritional replenishment and potentially improves prognosis. Chemotherapy alone is effective and should be prioritised in patients with metastatic disease a good performance status, and its impact on dysphagia should be determined before further interventions are planned. Regarding local treatments, the insertion of a covered self-expandable metallic stent is the most commonly used alternative, as it allows for the rapid relief of severe dysphagia. Although several randomised trials have highlighted the role of oesophageal brachytherapy, this technique is often not easily accessible. Contemporary trials are ongoing to better define the role of external radiation therapy. While awaiting these results, external radiation therapy can be considered as a second-best option for patients with a life-expectancy > 3 months. It is important to offer nutritional support and to integrate quality of life measures in the palliative management of dysphagia. This multidisciplinary international position paper aims to propose a decision-making process and highlight randomised trials for the management of malignant dysphagia in metastatic oesogastric cancer patients.

Identifiants

pubmed: 32563014
pii: S0959-8049(20)30235-5
doi: 10.1016/j.ejca.2020.04.032
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-112

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement Following authors declared financial support, but not related to this work: Other authors did not declare conflict of interest.

Auteurs

Antonin Levy (A)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. Electronic address: antonin.levy@gustaveroussy.fr.

Anna D Wagner (AD)

Department of Oncology, Division of medical oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Cyrus Chargari (C)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France.

Markus Moehler (M)

Department of Gastroenterology and Hepatology, Universitätsmedizin, Mainz, Germany.

Marcel Verheij (M)

Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.

Jérôme Durand-Labrunie (J)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Manon Kissel (M)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Erick Chirat (E)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Pascal Burtin (P)

Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Michel Ducreux (M)

Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Valérie Boige (V)

Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

Magnus Nilsson (M)

Division of Surgery, CLINTEC, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

Narikazu Boku (N)

Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Ian Chau (I)

Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UK.

Eric Deutsch (E)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH